Mn Services Vermogensbeheer B.V. Biomarin Pharmaceutical Inc Transaction History

Mn Services Vermogensbeheer B.V.

$14.3 Billion
Q3 2024

A detailed history of Mn Services Vermogensbeheer B.V. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Mn Services Vermogensbeheer B.V. holds 31,700 shares of BMRN stock, worth $2.01 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

31,700

Previous 31,700 -0.0%

Holding current value

$2.01 Million

Previous $2.61 Million 14.64%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$83.81 - $99.0 $4.56 Million - $5.39 Million	-54,400 Reduced 63.18%	31,700 $2.77 Million
Q4 2023 Jan 29, 2024	SELL	$76.22 - $98.51 $251,526 - $325,083	-3,300 Reduced 3.69%	86,100 $8.3 Million
Q2 2023 Aug 09, 2023	BUY	$86.68 - $100.3 $7.75 Million - $8.97 Million	89,400 New	89,400 $7.75 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $2.06 Million - $2.61 Million	-30,631 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$84.2 - $98.62 $42,100 - $49,310	500 Added 1.66%	30,631 $2.72 Million
Q4 2018 Feb 12, 2019	BUY	$80.14 - $106.07 $184,322 - $243,960	2,300 Added 8.26%	30,131 $2.24 Million
Q2 2018 Aug 13, 2018	SELL	$76.01 - $99.03 $91,212 - $118,836	-1,200 Reduced 4.13%	27,831 $2.62 Million
Q1 2018 May 11, 2018	BUY	$77.67 - $92.63 $147,573 - $175,997	1,900 Added 7.0%	29,031 $2.35 Million
Q4 2017 Feb 02, 2018	SELL	$80.76 - $95.13 $121,140 - $142,695	-1,500 Reduced 5.24%	27,131 $2.02 Million
Q3 2017 Nov 01, 2017	BUY	$80.6 - $94.95 $2.31 Million - $2.72 Million	28,631	28,631 $2.67 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mn Services Vermogensbeheer B.V., based on Form 13F filings with the SEC.

News

Stay updated on Mn Services Vermogensbeheer B.V. with notifications on news.

Account

Mn Services Vermogensbeheer B.V. Biomarin Pharmaceutical Inc Transaction History